{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T13:53:52Z","timestamp":1790430832420,"version":"4.1.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T00:00:00Z","timestamp":1589500800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T00:00:00Z","timestamp":1589500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Purpose<\/jats:title>\n<jats:p>Biomarkers are needed to guide treatment decisions in recurrent ovarian cancer, as a high proportion of patients do not benefit from treatments. Data on immune subsets in patients receiving chemotherapy are scarce. We investigated the impact of T cells, B cells, neutrophils and the neutrophil-lymphocyte ratio (NLR) in ovarian cancer patients receiving palliative chemotherapy.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Blood samples were collected prospectively at baseline in recurrent ovarian cancer (<jats:italic>N<\/jats:italic>\u2009=\u200972) receiving chemotherapy. T cells, B cells, neutrophils, and NLR were analyzed. Primary and secondary endpoints were overall survival (OS) and treatment response, respectively. Cut-offs for T and B cells were predefined.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>In patients with low vs. high T and B cells counts, OS was 6.1\u2009months vs 12.0\u2009months (<jats:italic>P<\/jats:italic>\u2009=\u20090.017) and 6.1\u2009months vs 12.0\u2009months (<jats:italic>P<\/jats:italic>\u2009=\u20090.011, respectively. Low T and B cells analyzed as continuous variables were also associated with unfavorable OS, <jats:italic>P<\/jats:italic>\u2009=\u20090.011 and <jats:italic>P<\/jats:italic>\u2009=\u20090.007, respectively. Neutrophils had no significant prognostic impact. Median NLR was 4.1. High vs. low NLR was associated with poor survival, 7.4\u2009months vs. 15.9\u2009months (<jats:italic>P<\/jats:italic>\u2009=\u20090.012). In multivariate analysis including platinum sensitivity, number of prior lines of chemotherapy, and performance status, high NLR remained an independent poor prognostic factor HR: 2.17 (95% CI 1.21\u20133.88) (<jats:italic>P<\/jats:italic>\u2009=\u20090.009). High NLR was also significantly associated with lack of response, OR 0.15 (95% CI: 0.04\u20130.51) (<jats:italic>P<\/jats:italic>\u2009=\u20090.002).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>In recurrent ovarian cancer patients undergoing palliative chemotherapy, low T and B lymphocyte counts had an unfavorable prognostic impact. High NLR was associated with lack of response and a poor prognosis, and the parameter may be used in patient counselling and treatment decisions.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13048-020-00661-4","type":"journal-article","created":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T15:06:48Z","timestamp":1589555208000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Prognostic significance of baseline T cells, B cells and neutrophil-lymphocyte ratio (NLR) in recurrent ovarian cancer treated with chemotherapy"],"prefix":"10.1186","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2905-5342","authenticated-orcid":false,"given":"Jon R\u00f8ikj\u00e6r","family":"Henriksen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Line","family":"Nederby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frede","family":"Donskov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Waldstr\u00f8m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parvin","family":"Adimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Jakobsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina Dahl","family":"Steffensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,15]]},"reference":[{"key":"661_CR1","doi-asserted-by":"publisher","unstructured":"Coleman RL, Fleming GF, Brady MF, et al. LBA3VELIA\/GOG-3005: Integration of veliparib (V) with front-line chemotherapy and maintenance in women with high-grade serous carcinoma of ovarian, fallopian tube, or primary peritoneal origin (HGSC). Ann Oncol. 2019;30(Supplement_5). https:\/\/doi.org\/10.1093\/annonc\/mdz394.054..","DOI":"10.1093\/annonc\/mdz394.054"},{"issue":"10","key":"661_CR2","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1093\/annonc\/mds203","volume":"23","author":"LC Hanker","year":"2012","unstructured":"Hanker LC, Loibl S, Burchardi N, et al. The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane\/platinum-based therapy. Ann Oncol. 2012;23(10):2605\u201312. https:\/\/doi.org\/10.1093\/annonc\/mds203.","journal-title":"Ann Oncol"},{"issue":"6","key":"661_CR3","doi-asserted-by":"publisher","first-page":"e540","DOI":"10.3747\/co.24.3824","volume":"24","author":"J Francis","year":"2017","unstructured":"Francis J, Coakley N, Elit L, Mackay H. Gynecologic Cancer disease site group TGCDS. Systemic therapy for recurrent epithelial ovarian cancer: a clinical practice guideline. Curr Oncol. 2017;24(6):e540\u20136. https:\/\/doi.org\/10.3747\/co.24.3824.","journal-title":"Curr Oncol"},{"issue":"7","key":"661_CR4","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1093\/annonc\/mdz135","volume":"30","author":"UA Matulonis","year":"2019","unstructured":"Matulonis UA, Shapira-Frommer R, Santin AD, et al. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. Ann Oncol. 2019;30(7):1080\u20137. https:\/\/doi.org\/10.1093\/annonc\/mdz135.","journal-title":"Ann Oncol"},{"issue":"5","key":"661_CR5","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Review hallmarks of Cancer : the next generation. Cell. 2011;144(5):646\u201374. https:\/\/doi.org\/10.1016\/j.cell.2011.02.013.","journal-title":"Cell"},{"issue":"1","key":"661_CR6","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.critrevonc.2013.03.010","volume":"88","author":"GJK Guthrie","year":"2013","unstructured":"Guthrie GJK, Charles KA, Roxburgh CSD, Horgan PG, McMillan DC, Clarke SJ. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol. 2013;88(1):218\u201330. https:\/\/doi.org\/10.1016\/j.critrevonc.2013.03.010.","journal-title":"Crit Rev Oncol Hematol"},{"key":"661_CR7","doi-asserted-by":"publisher","unstructured":"Templeton AJ, McNamara MG, \u0160eruga B, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: A systematic review and meta-analysis. J Natl Cancer Inst. 2014;106(6). https:\/\/doi.org\/10.1093\/jnci\/dju124.","DOI":"10.1093\/jnci\/dju124"},{"issue":"1","key":"661_CR8","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00262-008-0516-3","volume":"58","author":"H Cho","year":"2009","unstructured":"Cho H, Hur HW, Kim SW, et al. Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother. 2009;58(1):15\u201323. https:\/\/doi.org\/10.1007\/s00262-008-0516-3.","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"661_CR9","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1159\/000475911","volume":"41","author":"Q Huang","year":"2017","unstructured":"Huang Q, Zhou L, Zeng W-J, et al. Prognostic significance of neutrophil-to-lymphocyte ratio in ovarian Cancer: a systematic review and meta-analysis of observational studies. Cell Physiol Biochem. 2017;41(6):2411\u20138. https:\/\/doi.org\/10.1159\/000475911.","journal-title":"Cell Physiol Biochem"},{"issue":"3","key":"661_CR10","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1093\/annonc\/mds494","volume":"24","author":"S Banerjee","year":"2013","unstructured":"Banerjee S, Rusti G, Paul J, et al. A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG. Ann Oncol. 2013;24(3):679\u201387. https:\/\/doi.org\/10.1093\/annonc\/mds494.","journal-title":"Ann Oncol"},{"key":"661_CR11","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/1479-5876-11-189","volume":"11","author":"A Carus","year":"2013","unstructured":"Carus A, Gurney H, Gebski V, et al. Impact of baseline and nadir neutrophil index in non-small cell lung cancer and ovarian cancer patients: assessment of chemotherapy for resolution of unfavourable neutrophilia. J Transl Med. 2013;11:189. https:\/\/doi.org\/10.1186\/1479-5876-11-189.","journal-title":"J Transl Med"},{"issue":"1","key":"661_CR12","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ygyno.2018.07.025","volume":"151","author":"MP Pinto","year":"2018","unstructured":"Pinto MP, Balmaceda C, Bravo ML, et al. Patient inflammatory status and CD4+\/CD8+ intraepithelial tumor lymphocyte infiltration are predictors of outcomes in high-grade serous ovarian cancer. Gynecol Oncol. 2018;151(1):10\u20137. https:\/\/doi.org\/10.1016\/j.ygyno.2018.07.025.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"661_CR13","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ygyno.2011.09.039","volume":"124","author":"WT Hwang","year":"2012","unstructured":"Hwang WT, Adams SF, Tahirovic E, Hagemann IS, Coukos G. Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol Oncol. 2012;124(2):192\u20138. https:\/\/doi.org\/10.1016\/j.ygyno.2011.09.039.","journal-title":"Gynecol Oncol"},{"issue":"51","key":"661_CR14","doi-asserted-by":"publisher","first-page":"18538","DOI":"10.1073\/pnas.0509182102","volume":"102","author":"E Sato","year":"2005","unstructured":"Sato E, Olson SH, Ahn J, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+\/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A. 2005;102(51):18538\u201343. https:\/\/doi.org\/10.1073\/pnas.0509182102.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"661_CR15","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa020177","volume":"348","author":"L Zhang","year":"2003","unstructured":"Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348(3):203\u201313. https:\/\/doi.org\/10.1056\/NEJMoa020177.","journal-title":"N Engl J Med"},{"issue":"8","key":"661_CR16","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1093\/annonc\/mdu191","volume":"25","author":"HR Ali","year":"2014","unstructured":"Ali HR, Provenzano E, Dawson S-J, et al. Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients. Ann Oncol. 2014;25(8):1536\u201343. https:\/\/doi.org\/10.1093\/annonc\/mdu191.","journal-title":"Ann Oncol"},{"key":"661_CR17","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1200\/JCO.2010.30.5425","volume":"29","author":"B Mlecnik","year":"2011","unstructured":"Mlecnik B, Tosolini M, Kirilovsky A, et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol. 2011;29:610\u20138. https:\/\/doi.org\/10.1200\/JCO.2010.30.5425.","journal-title":"J Clin Oncol"},{"issue":"12","key":"661_CR18","doi-asserted-by":"publisher","first-page":"173290","DOI":"10.1001\/jamaoncol.2017.3290","volume":"3","author":"EL Goode","year":"2017","unstructured":"Goode EL. Dose-response relationship of cd8 + tumor infiltrating lymphocytes and survival time in high-grade serous ovarian cancer hhs public access. JAMA Oncol. 2017;3(12):173290. https:\/\/doi.org\/10.1001\/jamaoncol.2017.3290.","journal-title":"JAMA Oncol"},{"key":"661_CR19","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.clim.2011.08.013","volume":"141","author":"J Hamanishi","year":"2011","unstructured":"Hamanishi J, Mandai M, Abiko K, et al. The comprehensive assessment of local immune status of ovarian cancer by the clustering of multiple immune factors. Clin Immunol. 2011;141:338\u201347. https:\/\/doi.org\/10.1016\/j.clim.2011.08.013.","journal-title":"Clin Immunol"},{"issue":"4","key":"661_CR20","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1158\/1078-0432.CCR-16-1433","volume":"23","author":"CS Lo","year":"2017","unstructured":"Lo CS, Sanii S, Kroeger DR, et al. Neoadjuvant chemotherapy of ovarian cancer results in three patterns of tumor-infiltrating lymphocyte response with distinct implications for immunotherapy. Clin Cancer Res. 2017;23(4):925\u201334. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-1433.","journal-title":"Clin Cancer Res"},{"issue":"15_suppl","key":"661_CR21","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1200\/jco.2019.37.15_suppl.2625","volume":"37","author":"J Henriksen","year":"2019","unstructured":"Henriksen J, Donskov F, Waldstr\u00f8m M, et al. Tissue immune response in epithelial ovarian carcinoma. J Clin Oncol. 2019;37(15_suppl):2625. https:\/\/doi.org\/10.1200\/jco.2019.37.15_suppl.2625.","journal-title":"J Clin Oncol"},{"key":"661_CR22","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1007\/s00262-009-0733-4","volume":"58","author":"M Reuschenbach","year":"2009","unstructured":"Reuschenbach M, Von Knebel DM, Wentzensen N. A systematic review of humoral immune responses against tumor antigens. Cancer Immunol Immunother. 2009;58:1535\u201344. https:\/\/doi.org\/10.1007\/s00262-009-0733-4.","journal-title":"Cancer Immunol Immunother"},{"issue":"12","key":"661_CR23","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.trecan.2016.10.010","volume":"2","author":"GJ Yuen","year":"2016","unstructured":"Yuen GJ, Demissie E, Pillai S. B lymphocytes and Cancer: a love\u2013hate relationship. Trends Cancer. 2016;2(12):747\u201357. https:\/\/doi.org\/10.1016\/j.trecan.2016.10.010.","journal-title":"Trends Cancer"},{"key":"661_CR24","doi-asserted-by":"publisher","unstructured":"Gupta P, Chen C, Chaluvally-Raghavan P, Pradeep S. B Cells as an immune-regulatory signature in ovarian Cancer. Cancers. 2019;11(7). https:\/\/doi.org\/10.3390\/cancers11070894.","DOI":"10.3390\/cancers11070894"},{"issue":"7286","key":"661_CR25","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/nature08782","volume":"464","author":"M Ammirante","year":"2010","unstructured":"Ammirante M, Luo J-L, Grivennikov S, Nedospasov S, Karin M. B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature. 2010;464(7286):302\u20135. https:\/\/doi.org\/10.1038\/nature08782.","journal-title":"Nature"},{"issue":"1","key":"661_CR26","doi-asserted-by":"publisher","first-page":"4186","DOI":"10.1038\/s41467-019-12160-2","volume":"10","author":"J Griss","year":"2019","unstructured":"Griss J, Bauer W, Wagner C, et al. B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma. Nat Commun. 2019;10(1):4186. https:\/\/doi.org\/10.1038\/s41467-019-12160-2.","journal-title":"Nat Commun"},{"issue":"5","key":"661_CR27","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/J.CCR.2005.04.014","volume":"7","author":"KE de Visser","year":"2005","unstructured":"de Visser KE, Korets LV, Coussens LM. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell. 2005;7(5):411\u201323. https:\/\/doi.org\/10.1016\/J.CCR.2005.04.014.","journal-title":"Cancer Cell"},{"issue":"10","key":"661_CR28","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.2217\/imt.11.106","volume":"3","author":"T Sasada","year":"2011","unstructured":"Sasada T, Suekane S. Variation of tumor-infiltrating lymphocytes in human cancers: controversy on clinical significance. Immunotherapy. 2011;3(10):1235\u201351. https:\/\/doi.org\/10.2217\/imt.11.106.","journal-title":"Immunotherapy"},{"issue":"9","key":"661_CR29","doi-asserted-by":"publisher","first-page":"4977","DOI":"10.4049\/jimmunol.1001323","volume":"185","author":"BH Nelson","year":"2010","unstructured":"Nelson BH. CD20 + B cells: the other tumor-infiltrating lymphocytes. J Immunol. 2010;185(9):4977\u201382. https:\/\/doi.org\/10.4049\/jimmunol.1001323.","journal-title":"J Immunol"},{"issue":"8","key":"661_CR30","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1038\/nm.3909","volume":"21","author":"AJ Gentles","year":"2015","unstructured":"Gentles AJ, Newman AM, Liu CL, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. 2015;21(8):938\u201345. https:\/\/doi.org\/10.1038\/nm.3909.","journal-title":"Nat Med"},{"issue":"8","key":"661_CR31","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1038\/onc.2009.416","volume":"29","author":"F Pag\u00e8s","year":"2010","unstructured":"Pag\u00e8s F, Galon J, Dieu-Nosjean MC, Tartour E, Saut\u00e8s-Fridman C, Fridman WH. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene. 2010;29(8):1093\u2013102. https:\/\/doi.org\/10.1038\/onc.2009.416.","journal-title":"Oncogene"},{"issue":"3","key":"661_CR32","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1046\/j.0902-4441.2003.00199.x","volume":"72","author":"LR Bisset","year":"2004","unstructured":"Bisset LR, Lung TL, Kaelin M, Ludwig E, Dubs RW. Reference values for peripheral blood lymphocyte phenotypes applicable to the healthy adult population in Switzerland. Eur J Haematol. 2004;72(3):203\u201312. https:\/\/doi.org\/10.1046\/j.0902-4441.2003.00199.x.","journal-title":"Eur J Haematol"},{"issue":"2","key":"661_CR33","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","volume":"21","author":"GJS Rustin","year":"2011","unstructured":"Rustin GJS, Vergote I, Eisenhauer E, et al. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the gynecological Cancer intergroup (GCIG). Int J Gynecol Cancer. 2011;21(2):419\u201323. https:\/\/doi.org\/10.1097\/IGC.0b013e3182070f17.","journal-title":"Int J Gynecol Cancer"},{"key":"661_CR34","volume-title":"Resistance Mechanisms to Cancer Chemotherapy","author":"KM Redmond","year":"2008","unstructured":"Redmond KM, Wilson TR, Johnston PG, Longley DB. Resistance Mechanisms to Cancer Chemotherapy, vol. 5138; 2008."},{"issue":"5","key":"661_CR35","first-page":"495","volume":"36","author":"AS Lagan\u00e0","year":"2015","unstructured":"Lagan\u00e0 AS, Colonese F, Colonese E, et al. Cytogenetic analysis of epithelial ovarian cancer\u2019s stem cells: an overview on new diagnostic and therapeutic perspectives. Eur J Gynaecol Oncol. 2015;36(5):495\u2013505.","journal-title":"Eur J Gynaecol Oncol"},{"issue":"Suppl","key":"661_CR36","doi-asserted-by":"publisher","first-page":"S185","DOI":"10.1016\/j.semcancer.2015.03.004","volume":"35","author":"DS Vinay","year":"2015","unstructured":"Vinay DS, Ryan EP, Pawelec G, et al. Immune evasion in cancer: mechanistic basis and therapeutic strategies. Semin Cancer Biol. 2015;35(Suppl):S185\u201398. https:\/\/doi.org\/10.1016\/j.semcancer.2015.03.004.","journal-title":"Semin Cancer Biol"},{"key":"661_CR37","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.gore.2016.09.004","volume":"18","author":"AS Lagan\u00e0","year":"2016","unstructured":"Lagan\u00e0 AS, Sofo V, Vitale SG, Triolo O. Epithelial ovarian cancer inherent resistance: may the pleiotropic interaction between reduced immunosurveillance and drug-resistant cells play a key role? Gynecol Oncol Rep. 2016;18:57\u20138. https:\/\/doi.org\/10.1016\/j.gore.2016.09.004.","journal-title":"Gynecol Oncol Rep"},{"issue":"2","key":"661_CR38","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s00404-018-5006-z","volume":"299","author":"SG Vitale","year":"2019","unstructured":"Vitale SG, Capriglione S, Zito G, et al. Management of endometrial, ovarian and cervical cancer in the elderly: current approach to a challenging condition. Arch Gynecol Obstet. 2019;299(2):299\u2013315. https:\/\/doi.org\/10.1007\/s00404-018-5006-z.","journal-title":"Arch Gynecol Obstet"},{"issue":"2","key":"661_CR39","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.ygyno.2018.02.017","volume":"149","author":"MS Schuurman","year":"2018","unstructured":"Schuurman MS, Kruitwagen RFPM, Portielje JEA, Roes EM, Lemmens VEPP, van der Aa MA. Treatment and outcome of elderly patients with advanced stage ovarian cancer: a nationwide analysis. Gynecol Oncol. 2018;149(2):270\u20134. https:\/\/doi.org\/10.1016\/j.ygyno.2018.02.017.","journal-title":"Gynecol Oncol"},{"issue":"5","key":"661_CR40","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1007\/s005200050271","volume":"7","author":"AE Taylor","year":"1999","unstructured":"Taylor AE, Olver IN, Sivanthan T, Chi M, Purnell C. Observer error in grading performance status in cancer patients. Support Care Cancer. 1999;7(5):332\u20135. https:\/\/doi.org\/10.1007\/s005200050271.","journal-title":"Support Care Cancer"},{"issue":"3","key":"661_CR41","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.semcancer.2013.02.001","volume":"23","author":"F Donskov","year":"2013","unstructured":"Donskov F. Immunomonitoring and prognostic relevance of neutrophils in clinical trials. Semin Cancer Biol. 2013;23(3):200\u20137. https:\/\/doi.org\/10.1016\/j.semcancer.2013.02.001.","journal-title":"Semin Cancer Biol"},{"issue":"2","key":"661_CR42","first-page":"606","volume":"9","author":"AM Wolf","year":"2003","unstructured":"Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res. 2003;9(2):606\u201312.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"661_CR43","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.4049\/jimmunol.169.5.2756","volume":"169","author":"UK Liyanage","year":"2002","unstructured":"Liyanage UK, Moore TT, Joo H-G, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol. 2002;169(5):2756\u201361. https:\/\/doi.org\/10.4049\/jimmunol.169.5.2756.","journal-title":"J Immunol"},{"issue":"5","key":"661_CR44","doi-asserted-by":"publisher","first-page":"101042831769757","DOI":"10.1177\/1010428317697571","volume":"39","author":"Q He","year":"2017","unstructured":"He Q, Li G, Ji X, et al. Impact of the immune cell population in peripheral blood on response and survival in patients receiving neoadjuvant chemotherapy for advanced gastric cancer. Tumor Biol. 2017;39(5):101042831769757. https:\/\/doi.org\/10.1177\/1010428317697571.","journal-title":"Tumor Biol"},{"issue":"9","key":"661_CR45","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/nm1093","volume":"10","author":"TJ Curiel","year":"2004","unstructured":"Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10(9):942\u20139. https:\/\/doi.org\/10.1038\/nm1093.","journal-title":"Nat Med"},{"key":"661_CR46","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.oraloncology.2015.11.003","volume":"53","author":"X Zhou","year":"2016","unstructured":"Zhou X, Su Y-X, Lao X-M, Liang Y-J, Liao G-Q. CD19+IL-10+ regulatory B cells affect survival of tongue squamous cell carcinoma patients and induce resting CD4+ T cells to CD4+Foxp3+ regulatory T cells. Oral Oncol. 2016;53:27\u201335. https:\/\/doi.org\/10.1016\/j.oraloncology.2015.11.003.","journal-title":"Oral Oncol"},{"issue":"10","key":"661_CR47","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1093\/intimm\/10.10.1563","volume":"10","author":"H Nishimura","year":"1998","unstructured":"Nishimura H, Minato N, Nakano T, Honjo T. Immunological studies on PD-1-deficient mice: implication of PD-1 as a negative regulator for B cell responses. Int Immunol. 1998;10(10):1563\u201372. https:\/\/doi.org\/10.1093\/intimm\/10.10.1563.","journal-title":"Int Immunol"},{"issue":"10","key":"661_CR48","doi-asserted-by":"publisher","first-page":"5530","DOI":"10.4049\/jimmunol.165.10.5530","volume":"165","author":"C Pioli","year":"2000","unstructured":"Pioli C, Gatta L, Ubaldi V, Doria G. Inhibition of IgG1 and IgE production by stimulation of the B cell CTLA-4 receptor. J Immunol. 2000;165(10):5530\u20136. https:\/\/doi.org\/10.4049\/jimmunol.165.10.5530.","journal-title":"J Immunol"},{"issue":"2","key":"661_CR49","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1093\/intimm\/dxs098","volume":"25","author":"ML Thibult","year":"2013","unstructured":"Thibult ML, Mamessier E, Gertner-dardenne J, et al. Pd-1 is a novel regulator of human B-cell activation. Int Immunol. 2013;25(2):129\u201337. https:\/\/doi.org\/10.1093\/intimm\/dxs098.","journal-title":"Int Immunol"},{"issue":"4","key":"661_CR50","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252\u201364. https:\/\/doi.org\/10.1038\/nrc3239.","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"661_CR51","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1093\/annonc\/mdz166","volume":"30","author":"SL Gaillard","year":"2019","unstructured":"Gaillard SL, Coleman RL. Identifying markers of immune response in ovarian cancer: does PD-L1 expression meet the mark? Ann Oncol. 2019;30(7):1025\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdz166.","journal-title":"Ann Oncol"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-020-00661-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-020-00661-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-020-00661-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T23:24:52Z","timestamp":1621034692000},"score":1,"resource":{"primary":{"URL":"https:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-020-00661-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,15]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["661"],"URL":"https:\/\/doi.org\/10.1186\/s13048-020-00661-4","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,15]]},"assertion":[{"value":"16 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All patients provided signed informed consent before any study procedure, which included consent for publication. The Ethics Committee (S-20160049) and the Danish Data Protection Agency (16\/28860) approved the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no conflict of interest. The research was solely publicly funded.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"59"}}